Phase 1 trial results of jcar014 could someone please translate the second para. that begins "a subset of NHL patients"?
Dr. Turtle's presentation at ASH 2014 - CLL Support
Dr. Turtle's presentation at ASH 2014
Written by
jammerjer
To view profiles and participate in discussions please or .
1 Reply
•
Not what you're looking for?
You may also like...
ASH 2018: Dr. Kipps on antibodies and Venetoclax resistance
Society/Mayo Educational Forum, so if you are attending please say hello. Mayo has a ridiculously...
ASH 2017: Dr. Richard Furman on the importance of MCL-1 in CLL (chronic lymphocytic leukemia)
ibrutinib or rituximab. See this on the Murano trial from ASH 2017 that combined V+ rituximab. We...
Related Posts
- ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR
2022 ASH Conference Report: Should MPN Patients Follow the Mediterranean Diet?
Late breaking CLL abstract at ASH 2017 - VR vs BR- ASH 2019: A Clinical Trial of Cannabis As Targeted Therapy for Indolent Leukemic Lymphoma
- ASH 2019: U-MRD by subgroup (ibrutinib+venetoclax) CAPTIVATE trial
